依达拉奉、恩必普联合治疗脑梗死的疗效  

Edaravone and butylphthalide in treatment of acute cerebral infarction

作　　者：王秀杰[1] 

机构地区：[1]莱州市人民医院神经内科,261400

出　　处：《国际医药卫生导报》2016年第10期1445-1447,共3页International Medicine and Health Guidance News

摘　　要：目的探讨依达拉奉、恩必普联合治疗脑梗死的临床效果。方法收集本院2014年1月至2015年8月人院的160例脑梗死患者，随机分为对照组与联合组。对照组传统治疗，联合组加用依达拉奉与恩必普联合治疗，比较两组整体治疗效果、神经功能缺损、日常生活能力与不良反应。结果联合组治疗总有效率（83．75％）明显高于对照组（66．25％），差异有统计学意义（P〈0．05）；治疗后，联合组NIHSS评分（8．66±0．59）显著低于对照组（13．21±2．77），BI评分（79．52±11．75）显著高于对照组（61．13±10．51），差异有统计学意义（P〈0．01）；两组总体不良反应发生率差异无统计学意义（13．75％VS．7．50％，P〉0．05）。结论依达拉奉、恩必普联合治疗脑梗死临床效果显著，且安全性较高，具有借鉴性。Objective To investigate the curative effect ofedaravone and butylphthalide in the treatment of acute cerebral infarction. Methods 160 cerebral infarction patients admitted into our hospital from January, 2014 to August, 2015 was randomly divided into a control group and a combination group. The control group were conventionally treated; in addition, the combination group was treated with edaravone and butylphthalide. The overall treatment effect, neurologic impairment, activity of dialy living, and adverse reactions of these two groups were compared. Results The total effective rate （83.75%） of the combination group was significantly higher than that （66.25%） of the control group, with a statistical difference （P〈0.05）. After the treatment, the score of NIHSS was significantly lower and the score of BI was significantly higher in the combination group than in the control group [（8.66±0.59） vs. （13,21±2.77） and （79.52±11.75） vs. （61,13±10.51）], with statistical differences （P〈0.01）. There was no statistical difference in the incidence of adverse reactions （13.75% vs. 7.5%）between these two groups （P〉0.05）. Conclusions Edaravone in combination with butylphthalide for acute cerebral infarction is significantly effective, safe, and of reference in clinical practice.

关 键 词：依达拉奉 恩必普 脑梗死 总有效率 不良反应 

分 类 号：R743[医药卫生—神经病学与精神病学]